



Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?

Hannah Yejin Kim^{1,2}, Vitali Sintchenko^{3,4,5} and Jan-Willem Alffenaar^{1,2}

Affiliations: ¹Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. ²Westmead Hospital, Sydney, Australia. ³Sydney Medical School, The University of Sydney, Sydney, Australia. ⁴Centenary Institute, The University of Sydney, Sydney, Australia. ⁵Centre for Infectious Diseases and Microbiology–Public Health, Westmead Hospital, Sydney, Australia.

Correspondence: Jan-Willem Alffenaar, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia. E-mail: johannes.alfenaar@sydney.edu.au

 @ERSpublications

A combination of pharmacokinetics and pharmacodynamics is required to evaluate the efficacy of antimicrobial drugs in the treatment of *Mycobacterium abscessus* <http://bit.ly/2OGwS3C>

Cite this article as: Kim HY, Sintchenko V, Alffenaar J-W. Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?. *Eur Respir J* 2019; 54: 1901508 [<https://doi.org/10.1183/13993003.01508-2019>].

This single-page version can be shared freely online.

To the Editor:

We read with great interest the recent publication by KWAK *et al.* [1] involving a meta-analysis of studies reporting treatment outcomes for *Mycobacterium abscessus* pulmonary disease (MAB-PD). The authors should be commended for identifying the association between azithromycin, amikacin and imipenem, and improved clinical outcome in MAB-PD.